Raffaele, living with epilepsy

Delivering to become the next generation biopharma leader

UCB Corporate Presentation

June 2009

Disclaimer and safe harbour

2
the next generation biopharma leader June 2009

Forward-looking statements: This presentation includes forward-looking statements relating to UCB and Schwarz Pharma that are subject to known and unknown risks and uncertainties, many of which are outside of UCBs and Schwarz Pharmas control and are difficult to predict, that may cause actual results to differ materially from any future results expressed or implied from the forward-looking statements. In this presentation, the words anticipates, believes, estimates, seeks, expects, plans, intends and similar expressions, as they relate to UCB or Schwarz Pharma, are intended to identify forward-looking statements. Important factors that could cause actual results to differ materially from such expectations include, without limitation: the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms; the inability to integrate successfully Schwarz Pharma within UCB or to realize synergies from such integration following the acquisition; costs related to the acquisition of Schwarz Pharma; the economic environment of the industries in which UCB and Schwarz Pharma operate; costs associated with research and development; changes in the prospects for products in the pipeline or under development by UCB or Schwarz Pharma; dependence on the existing management of UCB and Schwarz Pharma; changes or uncertainties in Belgian or German tax laws or the administration of such laws; changes or uncertainties in the laws or regulations applicable to the markets in which UCB and Schwarz Pharma operate. All written and oral forward-looking statements attributable to UCB or Schwarz Pharma or persons acting on either of their behalf are expressly qualified in their entirety by the cautionary statements above. Neither UCB nor Schwarz Pharma intend, or undertake any obligation, to update these forward-looking statements.

UCB
3
the next generation biopharma leader June 2009

Vision
To become the next generation biopharmaceutical leader

To provide breakthrough innovation for patients suffering

from severe diseases

Therapeutic focus
Central nervous system (CNS)

Immunology

Foundation
UCB = UCB Pharma + Celltech (2004) + Schwarz Pharma (2006) UCB = unique combination of large, antibody-based molecules and

small, chemically-derived molecules

UCB
Our road map
4
the next generation biopharma leader June 2009

Breakthrough
Launch a new generation of therapies offering breakthrough innovation to patients with severe disease

Intense growth
Execution
Launch

Realise the commercial potential of new products

new products Invest in R&D SHAPE the organisation for the future Prioritise products and markets Improve competitiveness and profitability

2007

2010

... and beyond

2008 UCB continues on track

5
the next generation biopharma leader June 2009

SHAPE: major steps taken to accelerate the transformation of the organisation and to increase focus on UCB core disease areas, products and geographies 2008: three new molecular entities (NMEs) approved in the U.S. 2008/2009: major product launches - Vimpat, Neupro, Cimzia - ongoing and in preparation In-line with financial guidance

2008 Financial highlights

6
the next generation biopharma leader June 2009

Revenue of 3 601 million in line with previous year Recurring EBITDA of 733 million (-1%) Net profit 42 million (-74%) impacted by:
Significant restructuring expenses and fixed asset impairment charges related to the SHAPE programme Financial expenses related to purchase of minority Schwarz Pharma

shares

Adjusted1 net profit 270 million (-7%)

Adjusted for after-tax impact of one-off items, contribution from discontinued operations and inventory step-up

2008 7 regulatory approvals and 6 filings

7
the next generation biopharma leader June 2009

Seven regulatory approvals

Cimzia Keppra XR

Crohn's disease (U.S.) - launched Adjunctive therapy in epilepsy (U.S.) - launched

Neupro
Toviaz Vimpat Vimpat Xyzal

Restless legs syndrome (EU) launch expected H1 2009

Overactive bladder (U.S.) licensed to Pfizer Adjunctive therapy in epilepsy (EU) - launched Adjunctive therapy in epilepsy (U.S.) - launch expected Q2 2009 Antihistamine oral solution (U.S.) - launched

Six filings
Cimzia Cimzia Keppra

Rheumatoid arthritis (EU) Rheumatoid arthritis (U.S.) Adjunctive therapy in epilepsy (infants and children1 U.S.)

Keppra
Keppra Keppra XR

Adjunctive therapy in epilepsy (infants and children1 EU)

Adjunctive therapy in epilepsy (Japan) Adjunctive therapy in epilepsy (U.S.)

For children aged from one month to under four years

2008 Most NME approvals in the U.S.

8

Three out of 24 NME1 approvals in 2008 for UCB and one out of four Biologics License Applications (BLA) approved
3

the next generation biopharma leader June 2009

AS

RMA

0
ARE LLAS AD O LOR AMG EN ER H LT HC ASTE

NE

BS WYE T

GEN ZYM E

ING GE H EALT HCA RE

TI BO TEC

CEP HALO N

HAR M

AIL A MER IC

PRO GEN IC

ERA

UCB

GLA XOS MI TH KLI

WAT SON LA

FER R

PHA

MED

JANS

O MC NEIL

ORT H

1 2 3 4

New Molecular Entity - Source: FDA website Adolor and GlaxoSmithKline collaborated on Entereg Progenics and Wyeth collaborated on Relistor Toviaz (Pfizer), Vimpat (Schwarz Pharma) and Cimzia are all grouped under UCB - Toviaz is officially listed on FDA site as Pfizer. NDA filed by Schwarz Pharma and while approvable, was transferred to Pfizer

REG ENE

BIO V

BAY

SIRIO

H PH ARM

EPIX

RO N P

N TH

S I NC

EISA I

S CO

SEN

UCB4
3

2008 4 + 1 new product launches

9
the next generation biopharma leader June 2009

Crohn's disease
Launched in the U.S. Adjunctive therapy in epilepsy Launched in Germany and U.K. Adjunctive therapy in epilepsy Launched in the U.S.

Oral antihistamine solution

Launched in the U.S. Overactive bladder Launched in the EU, by Pfizer

Toviaz

Solid CNS & immunology pipeline Key projects

10
the next generation biopharma leader June 2009

Phase I
CDP7851 bone loss disorders CDP6038 autoimmune diseases

Phase II
CDP323 multiple sclerosis epratuzumab systemic lupus erythematosus

Phase III
Vimpat epilepsy monotherapy - U.S. Vimpat diabetic neuropathic pain - EU + U.S. brivaracetam epilepsy Keppra XR epilepsy monotherapy - U.S.

Filed
Neupro adv. Parkinson's disease - U.S1 Neupro restless legs syndrome - U.S.1 Cimzia rheumatoid arthritis - EU

Approved
Neupro restless legs syndrome EU2

Cimzia Crohn's disease EU

CNS

Immunology

1 2

Neupro Complete Response Letter (December 2008) CHMP recommends lifting of treatment restrictions for Neupro in Europe (May 2009)

CNS Expansion in our core area

11
the next generation biopharma leader June 2009

Epilepsy

Vimpat brivaracetam

Parkinson's disease (PD)

Restless legs syndrome (RLS) Diabetic neuropathic pain (DNP) Multiple sclerosis (MS)

Neupro
Neupro Vimpat CDP323

Epilepsy Major unmet medical need

12
the next generation biopharma leader June 2009

High unmet medical need in ~1/3 of treated epilepsy patients

50%

25-30%
20-25%

Controlled on 1st monotherapy Uncontrolled despite 2-3 AEDs "Controlled" on more than 1 AED

Patients with only one seizure/month report significant impact on their social life, ability to work and standard of living
No new AEDs1 approved in over 5 years (U.S.) Few future treatments expected, particularly with a novel mode of action

There is a strong need for a new treatment option

Antiepileptic drug

Vimpat in epilepsy a new treatment option Monotherapy Phase III programme ongoing
13
the next generation biopharma leader June 2009

Novel dual mode of action Easy to use

No clinically significant drug-drug interactions Multiple formulations: tablets, syrup, IV

Monotherapy Phase III trial in the U.S. ongoing

U.S. market = 70% of monotherapy market
Lakeisha, living with epilepsy

Phase I

Phase II

Phase III

Filed August 2007 November 2007

Approved September 2008 October 2008

Launched September 2008 May 2009

Vimpat (lacosamide) Vimpat (lacosamide) Vimpat (lacosamide)

Epilepsy Adjunctive therapy (EU) Epilepsy Adjunctive therapy (U.S.) Epilepsy Monotherapy (U.S.)
Results expected Q2 2011

Vimpat has been designated as a Schedule V controlled substance by U.S. regulators.

Brivaracetam in epilepsy Phase III programme ongoing

14
the next generation biopharma leader June 2009

Broader mechanism of action than Keppra Population includes patients not controlled with Keppra

Phase III top line results (April 2009):

Study N01253 met its primary efficacy endpoint Study N01252 did not meet its primary efficacy endpoint Study N01254 confirmed brivaracetam was well tolerated Further analysis will be conducted Regulatory authorities will be consulted to determine next steps

Path forward update expected by year end

Phase I Phase II Phase III April 2009 Filed Approved Launched

Brivaracetam

Epilepsy adjunctive therapy

Neupro in Parkinson's disease Getting closer to make it available for new patients in Europe
15
the next generation biopharma leader June 2009

Deviation from product approved specification Restriction on promotion (June 2008)

To manage potential shortages: existing patients only

Full cold storage and distribution chain implemented (September 2008) CHMP1 positive opinion (May 2009) recommending:

Lifting of treatment restrictions for Neupro in Europe Allowing Neupro to be available to all patients with Parkinsons disease
Terry, living with Parkinsons disease

Phase I

Phase II

Phase III

Filed

Approved February 2006 January 2007

Launched March 2006 January 2007

Neupro (rotigotine) Neupro (rotigotine)

Early stage Parkinson's disease (EU) Advanced Parkinson's disease (EU)

CHMP: EMEA's Committee for Medicinal Products for Human Use

Neupro in Parkinson's disease

Working to make it available for new patients in the U.S.
16
the next generation biopharma leader June 2009

Deviation from product approved specification Product recall (March 2008)

Out-of-stock situation

FDA Complete Response Letter (December 2008)

Substantial evidence of effectiveness in advanced Parkinsons disease and restless legs syndrome (RLS) Dialogue ongoing with the FDA to bring Neupro back to U.S. patients
Wolfgang, living with Parkinsons disease

Phase I

Phase II

Phase III

Filed

Approved May 2007

Launched July 2007

Neupro (rotigotine) Neupro (rotigotine)

Early stage Parkinson's disease (U.S.) Advanced Parkinson's disease (U.S.)

December 2007

Neupro in restless legs syndrome

Increased awareness of an unrecognised disease
17

Demonstrated efficacy and well tolerated Consistent results within comprehensive clinical program

the next generation biopharma leader June 2009

Improved sleep and reduced daytime tiredness Potential first line treatment EU approval (September 2008)

FDA Complete Response Letter (December 2008)

Substantial evidence of effectiveness in advanced Parkinsons disease and restless legs syndrome (RLS)
Sten, living with restless legs syndrome

CHMP positive opinion (May 2009)

Recommends allowing Neupro to be launched for the treatment of moderate to severe RLS

Phase I

Phase II

Phase III

Filed

Approved September 2008

Launched

Neupro (rotigotine)
Neupro (rotigotine)

Restless legs syndrome (EU)

Restless legs syndrome (U.S.)
December 2007

Vimpat in diabetic neuropathic pain Path forward to be elaborated

18
the next generation biopharma leader June 2009

Promising drug for a large unmet medical need

Demonstrated sustained efficacy and good tolerability No drug-drug / food interactions, no weight gain

New mode of action

FDA Not Approvable Letter (July 2008) Withdrawal of MAA1 in EU (September 2008) Optimise design of future studies to meet conservative statistical requirements and then discuss with authorities UCB decision expected H2 2009
Frieda, living with diabetic neuropathic pain

Phase I

Phase II

Phase III

Filed

Approved

Launched

Vimpat (lacosamide) Vimpat (lacosamide)

Diabetic neuropathic pain (EU) Diabetic neuropathic pain (U.S.)

Marketing Authorisation Application

CDP323 in multiple sclerosis Oral administration

19
the next generation biopharma leader June 2009

Potent and orally active small molecule antagonist of alpha 4-integrin Successful collaboration with Biogen IDEC Phase II programme ongoing

Phase I

Phase II Results expected 2010

Phase III

Filed

Approved

Launched

CDP323

Multiple sclerosis

Immunology
20
the next generation biopharma leader June 2009

Crohn's disease (CD) Rheumatoid arthritis (RA)

Cimzia Cimzia

Bone loss disorders

Systemic lupus erythematosus (SLE)

CDP7851
epratuzumab

Cimzia in rheumatoid arthritis Only PEGylated Fc-free anti-TNF

21
the next generation biopharma leader June 2009

Approved and launched in the U.S. Filed with European authorities (July 2008)
Review pending

Alison, living with rheumatoid arthritis

Phase I

Phase II

Phase III

Filed February 2008 July 2008

Approved May 2009

Launched May 2009

Cimzia (certolizumab pegol) Cimzia (certolizumab pegol)

Rheumatoid arthritis (U.S.) Rheumatoid arthritis (EU)

CDP7851 in bone loss disorders Novel therapy with strong potential

22
the next generation biopharma leader June 2009

Development of novel anabolic therapy

Antibody to sclerostin potentially treating bone loss

Study of naturally occurring human disorder leads to a potential new drug therapy

disorders, incl. osteoporosis

Collaborative project with Amgen Phase I: first positive results

UCB and Amgen are encouraged by the first-in-

human data and are currently planning the future development program
Normal Sclerosteosis

Phase I

Phase II

Phase III

Filed

Approved

Launched

CDP7851 (anti-sclerostin)

Bone loss disorders

Results expected H2 2009

Epratuzumab in systemic lupus erythematosus (SLE) Phase IIb study ongoing

23
the next generation biopharma leader June 2009

Analyses of recently closed clinical trials suggest a favourable efficacy and tolerability profile Phase IIb dose ranging study ongoing
Number of randomized patients: 210 Arms/doses: 6 arms dose range (from 150 3 600 mg/cycle) Duration: 3 months treatment phase Primary endpoint: reduction disease activity Population: patients with moderate/severe activity

Phase I

Phase II Results expected Q3 2009

Phase III

Filed

Approved

Launched

Epratuzumab

Systemic lupus erythematosus

Solid CNS & immunology pipeline Key projects

24
the next generation biopharma leader June 2009

Phase I
CDP7851 bone loss disorders CDP6038 autoimmune diseases

Phase II
CDP323 multiple sclerosis epratuzumab systemic lupus erythematosus

Phase III
Vimpat epilepsy monotherapy - U.S. Vimpat diabetic neuropathic pain - EU + U.S. brivaracetam epilepsy Keppra XR epilepsy monotherapy - U.S.

Filed
Neupro adv. Parkinson's disease - U.S1 Neupro restless legs syndrome - U.S.1 Cimzia rheumatoid arthritis - EU

Approved
Neupro restless legs syndrome EU2

Cimzia Crohn's disease EU

CNS

Immunology

1 2

Neupro Complete Response Letter (December 2008) CHMP recommends lifting of treatment restrictions for Neupro in Europe (May 2009)

SHAPE Transformation and focus

25
the next generation biopharma leader June 2009

Focus on CNS and immunology Focus on core products and geographies

Drive for breakthrough innovation for patients with severe disease

Simplify the organisation Improve competitiveness and profitability

SHAPE Achievements so far

26
the next generation biopharma leader June 2009

Organisation simplified and focused

Workforce already reduced by 15%

Resources reallocated to core assets Pre-clinical oncology portfolio incubated with Wilex (January 2009)
UCB retains buy-back options

Non-strategic emerging markets divested to GSK (January 2009) Equasym IR/XL and Somatostatine-UCB divested (February 2009)

UCB NewMedicines
Drug discovery to proof-of-concept organisation New external focus reinforced through new partnerships with academic

collaborations
CDP6038 (IL-6) for auto-immune diseases entered Phase I (December 2008)

UCB priorities for 2009

27
the next generation biopharma leader June 2009

Successfully launch Vimpat, Neupro, Cimzia Continue delivery of late stage pipeline

SHAPE:
Maximise core assets, optimise non-core assets Fully implement new organisational and geographical footprint

Prepare for Breakthrough Phase by building pipeline and strengthening new biopharma capabilities Foster patient centricity as a key driver of performance

2009 financial outlook

28
the next generation biopharma leader June 2009

Revenue expected to reach between 3.1 - 3.3 billion

Full generic competition to Keppra in the U.S for the whole year Partially compensated by newly launched products

Recurring EBITDA target increased to greater than 680 million

Swift implementation of the SHAPE programme

Net Profit expected to exceed 130 million

Excluding expected capital gains resulting from already announced

divestments

2009 Major milestones

29
the next generation biopharma leader June 2009

Brivaracetam in epilepsy Cimzia in rheumatoid arthritis

Phase III top line results U.S. approval & launch

Vimpat

in epilepsy1

Launch in the U.S.

First Phase IIb results Phase I to complete

Q3 2009 H2 2009

Epratuzumab in SLE CDP7851 in bone loss disorders

Vimpat has been designated as a Schedule V controlled substance by U.S. regulators. Adjunctive therapy in epilepsy

2009 2 + 1 product launches so far

30
the next generation biopharma leader June 2009

Rheumatoid arthritis
Launched in the U.S. Adjunctive therapy in epilepsy Launched in the U.S. Overactive bladder Launched in the U.S., by Pfizer

Toviaz

UCB
Our road map
31
the next generation biopharma leader June 2009

Breakthrough
Launch a new generation of therapies offering breakthrough innovation to patients with severe disease

Intense growth
Execution
Launch

Realise the commercial potential of new products

new products Invest in R&D SHAPE the organisation for the future Prioritise products and markets Improve competitiveness and profitability

2007

2010

... and beyond

32

the next generation biopharma leader June 2009

Appendix

Epilepsy
33
the next generation biopharma leader June 2009

The most common serious neurological disorder Excessive electrical activity in part or all of the brain resulting in recurrent seizures In most cases, there is no known cause for epilepsy Can affect anyone regardless of age, gender or ethnicity There is no known cure at this time but treatments are available to reduce the frequency and severity of seizures Prevalence: Market size: 6 million patients in 7 major markets1 3.2 billion in 7 major markets2 (2007)

1 2

PatientBase, Decision Resources - 2008 IMS, 2008 - Sales in epilepsy only. Japan not included. U.S. = Retail + Non-Fed hospitals

Parkinsons disease (PD)

34
the next generation biopharma leader June 2009

CNS disorder, which is the result of the loss of dopamine-producing brain cells Primary symptoms are tremor and trembling; stiffness of the limbs and trunk; slowness of movement and impaired balance and coordination No cure but a variety of medications provide relief from the symptoms Prevalence: 3 million patients in 7 major markets1

Market size:

790 million in 7 major markets2 (2007)

1 2

PatientBase, Decision Resources - 2008 Sales in PD only - EU 5 only. Source: IMS, 2008

Restless legs syndrome (RLS)

35
the next generation biopharma leader June 2009

Neurological condition that is characterised by the irresistible urge to move the legs The cause is unknown in most patients, but is suspected to be related to lack of dopamine in the brain It is a lifelong condition for which there is no cure Few treatments available to treat moderate to severe RLS

Prevalence:
Market size:

54 million patients in 7 major markets1

100 million in 7 major markets2 (2007)

1 2

PatientBase, Decision Resources - 2008 Sales in RLS only. Source: IMS, EU5, Mat 11/08

Diabetic neuropathic pain (DNP)

36
the next generation biopharma leader June 2009

Pain associated with a functional abnormality of the nervous system Several sub-types of neuropathic pain exist Symptoms depend on the type of nerves affected and are often associated with damage to the motor nerve such as muscle weakness, cramps, and spasms Very difficult to treat with only some 40-60% of patients achieving partial relief Prevalence: Market size: 10 million patients in 7 major markets1 390 million in 7 major markets2 (2007)

1 2

PatientBase, Decision Resources - 2008 Decision Resources Neuropathic Pain April 2007

Multiple sclerosis (MS)

37
the next generation biopharma leader June 2009

Chronic, inflammatory, demyelinating disease that affects the central nervous system (CNS) Affects the ability of nerve cells in the brain and spinal cord to communicate with each other Cause not known and affects women more than men No cure but medicines to slow it down, help control symptoms, prevent new attacks, and prevent disability are available Prevalence: Market size: 536 000 patients in 7 major markets1 4.3 billion in 7 major markets2 (2007)

1 2

PatientBase, Decision Resources 2008 Decision Resources Pharmacor: Multiple Sclerosis June 2008

Crohns disease (CD)

38
the next generation biopharma leader June 2009

Autoimmune disease that causes chronic inflammation of the GI tract Also referred to as Inflammatory Bowel Disease (IBD)

The cause is not known

Chronic condition, which means you have for life The disease tends to fluctuate between periods of remission and relapse There is no known cure for CD but treatments can help reduce symptoms Prevalence: Market size: 0.9 million patients in 7 major markets1 0.9 billion in 7 major markets2

1 2

PatientBase, Decision Resources 2008 Datamonitor - Autoimmune Overview Forecast: Crohns Disease December 2007

Rheumatoid arthritis (RA)

39
the next generation biopharma leader June 2009

Autoimmune disease that causes chronic and progressive inflammation of the joints Debilitating systemic condition The cause of rheumatoid arthritis is not known Symptoms come and go, depending on the degree of tissue inflammation There is no known cure for RA but treatments can reduce joint inflammation and pain, maximize joint function, and prevent joint destruction and deformity Prevalence: Market size: 5 million patients in 7 major markets1 5.8 billion in 7 major markets2 (2007)

1 2

PatientBase, Decision Resources 2008 Decision Resources Pharmacor: Rheumatoid Arthritis June 2008

Bone loss disorders

40
the next generation biopharma leader June 2009

Reduction of bone mass (density) or presence of a fragility fracture High associated morbidity and loss of daily independence caused by disease Treatments available for osteoporosis but significant need to improve the quality of bone restored Prevalence: Market size: 64 million patients in 7 major markets1 5.7 billion in 7 major markets2 (2007)

1 2

PatientBase, Decision Resources - 2008 Osteoporosis Datamonitor Commercial Insight :Osteoporosis June 2007

Systemic Lupus Erythematosus (SLE)

41
the next generation biopharma leader June 2009

Autoimmune disease that causes inflammation and damage to various body tissues The word "systemic" means the disease can affect many parts of the body The cause is not known (usually first affects people between the ages of 15 and 45 years) The symptoms may be mild or serious, most common ones include extreme fatigue, painful or swollen joints (arthritis), unexplained fever and skin rashes There is no known cure for SLE but it can be effectively treated with drugs, and most people with the disease can lead active, healthy lives

Prevalence:
Market size:

0.6 million patients in 7 major markets1

670 million in 7 major markets2 (2007)

1 2

PatientBase, Decision Resources - 2008 Datamonitor, IMS data taking into account off-label sales: both minimum and maximum sales - Mar08

Leading products compensate for Zyrtec decline

42
the next generation biopharma leader June 2009

million Leading products Keppra Zyrtec (incl. D/Cirrus) Xyzal 3 Tussionex Nootropil New products Neupro Cimzia Vimpat Total net sales

2008

YTD Change Actual1 CER2 23% -49% 3% 29% -8% 30% -50% 4% 38% -7%

1 266 249 173 147 93

58 10 2 3 027

12% -5%

16% -2%

1 2 3

Actual: change from previous year unadjusted for foreign currency impact CER: change from previous year adjusted for constant exchange rates Excluding Xyzal U.S. revenue to UCB of 39 million from profit-sharing with sanofi-aventis

2008 net sales

Geography
43
the next generation biopharma leader June 2009

2008 net sales

3 027 million

2007 net sales

3 188 million

Rest of World 13%

Rest of World 12%

North America 40%

Europe 47%
North America 46%

Europe 42%

2008 net sales Therapy area

44
the next generation biopharma leader June 2009

2008 net sales 3 027 million

2007 net sales 3 188 million

Other 39%

CNS 47%
Immunology & allergy 14%

Other 42%

CNS 37%

Immunology and allergy 21%

Employees Geography - 2008

45
the next generation biopharma leader June 2009

Total number of employees

11 292

16%

21%

20%

13% 9% 21%

Belgium U.K. Rest of EU

Germany U.S. Emerging Markets

2009 Corporate financial calendar

46
the next generation biopharma leader June 2009

2009 half-year results Interim update (nine months report)

31 July 22 October

Your Investor Relations team

47
the next generation biopharma leader June 2009

Antje Witte, Vice President Corporate Communications & Investor Relations

Phone +32 2 559 9414

E-mail: antje.witte@ucb.com

Richard Simpson, Senior Director Investor Relations

Phone: +32 2 559 9494 E-mail: richard.simpson@ucb.com

Michael Tuck-Sherman, Investor Relations Manager

Phone: +32 2 559 9712 E-mail: michael.tuck-sherman@ucb.com

Isabelle Ghellynck, Investor Relations Project Manager

Phone: +32 2 559 9588 E-mail: isabelle.ghellynck@ucb.com